ProStrakan partners with NewBridge for Sancuso
Galashiels, Scotland-based ProStrakan has signed an exclusive licence and supply agreement with United Arab Emirates-based NewBridge Pharmaceuticals for Sancuso, ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting for the Middle East and Africa.
Under the terms of the agreement, covering 59 countries across the Middle East and Africa, ProStrakan will receive undisclosed upfront and milestone payments, subject to the achievement of certain approvals and sales targets. NewBridge will be required to purchase Sancuso directly from ProStrakan at a pre-agreed price. In September, ProStrakan received approval from the US Food and Drug Administration for Sancuso and the product was launched in the USA this week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze